Key result
Sodium-glucose cotransporter 2 inhibitors demonstrate consistent effects in heart failure with preserved ejection fraction regardless of comorbid chronic obstructive pulmonary disease.
Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial discusses the efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction and comorbid COPD.
This article refers to 'Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER' by J.H. Butt et al.,
No takes yet. Share an insight, caveat, or question.
Hage et al. (2023) studied this question. Sodium-glucose cotransporter 2 inhibitors demonstrate consistent effects in heart failure with preserved ejection fraction regardless of comorbid chronic obstructive pulmonary disease.
Synapse has enriched 10 related papers. Consider them for comparative context: